HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SAR125844

inhibits MET tyrosine kinase; structure in first source

Also Known As:

1-(6-(6-(4-fluorophenyl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - SAR125844: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - Benzothiazoles: 40
        SAR125844: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzothiazoles: 40
      - SAR125844: 2

Experts

1.	Ahn, Jin-Hee: 1 article (10/2017)
2.	Assadourian, Sylvie: 1 article (10/2017)
3.	Bang, Yung-Jue: 1 article (10/2017)
4.	Doi, Toshihido: 1 article (10/2017)
5.	Gomez, Corinne: 1 article (10/2017)
6.	Goto, Masahiro: 1 article (10/2017)
7.	Hamauchi, Satoshi: 1 article (10/2017)
8.	Harnois, Marzia: 1 article (10/2017)
9.	Kim, Hyo Song: 1 article (10/2017)
10.	Kim, Tae Min: 1 article (10/2017)

Related Diseases

1.	Stomach Neoplasms (Stomach Cancer) 10/03/2017 - "Single-agent SAR125844 administered up to 570 mg/m2 has acceptable tolerability and modest antitumor activity in patients with MET-amplified gastric cancer." 10/03/2017 - "This was an open-label, phase I, multicenter, dose-escalation, and dose-expansion trial of SAR125844 in Asian patients with solid tumors, a subgroup of whom had gastric cancer and MET amplification (NCT01657214). " 02/01/2015 - "Daily or every-2-days intravenous treatment of SAR125844 promoted a dose-dependent tumor regression in MET-amplified human gastric cancer models at tolerated doses without treatment-related body weight loss. " 10/03/2017 - "Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer."
2.	Neoplasms (Cancer) 10/03/2017 - "This was an open-label, phase I, multicenter, dose-escalation, and dose-expansion trial of SAR125844 in Asian patients with solid tumors, a subgroup of whom had gastric cancer and MET amplification (NCT01657214). " 02/01/2015 - "Our data demonstrated that SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile, supporting its clinical development in patients with MET-amplified and MET pathway-addicted tumors." 02/01/2015 - "In two MET-amplified human gastric tumor xenograft models, SNU-5 and Hs 746T, intravenous treatment with SAR125844 leads to potent, dose- and time-dependent inhibition of the MET kinase and to significant impact on downstream PI3K/AKT and RAS/MAPK pathways. " 02/01/2015 - "The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer." 02/01/2015 - "Daily or every-2-days intravenous treatment of SAR125844 promoted a dose-dependent tumor regression in MET-amplified human gastric cancer models at tolerated doses without treatment-related body weight loss. "
3.	Body Weight (Weight, Body) 02/01/2015 - "Daily or every-2-days intravenous treatment of SAR125844 promoted a dose-dependent tumor regression in MET-amplified human gastric cancer models at tolerated doses without treatment-related body weight loss. "

Related Drugs and Biologics

1.	Tyrosine Kinase Inhibitors
2.	Protein-Tyrosine Kinases (Tyrosine Kinase)
3.	Phosphotransferases (Kinase)